CARMAT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.8 EUR | 0.00% |
|
-2.06% | -43.28% |
| Mar. 25 | Carmat: final agreement with creditors | CF |
| Mar. 25 | Carmat Secures Two-year Extensions for Bank Loans | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
2024-04-23
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.8
EUR
Average target price
14.22
EUR
Spread / Average Target
+274.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.28% | 100M | |
| +9.35% | 128B | |
| -10.36% | 10.42B | |
| -1.13% | 8.81B | |
| +18.54% | 7.38B | |
| +19.68% | 4.86B | |
| +7.75% | 3.43B | |
| -1.34% | 3.08B | |
| -16.08% | 2.01B | |
| -12.31% | 1.96B |
- Stock Market
- Equities
- ALCAR Stock
- News CARMAT
- French Medical Device Group Carmat Launches $33 Million Global Offering
